EIC funding call for RNA-based therapies and diagnostics for rare genetic diseases

The EIC Transition 2022 (HORIZON-EIC-2022-TRANSITION-01) call, which has opened on March 1st, is intended to meet the following specific objectives:

1. Advance, beyond the state-of-the-art, RNA delivery methods, including robust mRNA formulations, that would enable effective and safe delivery of mRNA into the cells;
2. Design, develop and preclinical validate of novel miRNAs (miRNA lncRNA, tRNA or siRNA-based) therapies for complex or rare genetic diseases;
3. Develop and validate novel RNA-based diagnostics and RNA-based predictive biomarkers that would allow for early and more accurate diagnosis and for favourable or non- post-treatment prognosis, respectively.

For more information please visit EJP RD website.